Araris Biotech, a Zurich, Switzerland-based developer of proprietary antibody-drug conjugates (ADCs), closed CHF2.5M seed financing round.
Backers included Redalpine, Schroder Adveq and VI Partners.
The company intends to use the funds for the development of its own antibody-drug-conjugates (ADCs).
Led by Chief Executive Officer Dr. Philipp Spycher, Araris Biotech is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug conjugate (ADC)-linker technology. Its innovative platform allows for the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering. The resulting ADCs have a defined drug-to-antibody ratio, are stable and monomeric.